23andMe
polygenic scores may predict safety and efficacy is incorporating clinical into our clinical trials use of polygenic scores could enable more efficient clinical development and improve the probability of success developing drugs in genetically defined patient populations may differentiate products based on better outcomes and improved benefit risk profiles providing the right drugs to the right patients | 23andMe
Company
Deck Type
Sector
Industry
Deck date
January 2022
Slide
53 of 78
Related slides by other companies
DICE Therapeutics
Results
March 2023
key from phase efficacy results dice | DICE Therapeutics
Exscientia
Investor Presentation
October 2023
major reasons clinical trials fail | Exscientia
BrainStorm Cell Therapeutics
Investor Presentation
October 2022
clinical outcomes considered as measure of efficacy | BrainStorm Cell Therapeutics
Exscientia
Investor Presentation
August 2023
major reasons clinical trials fail | Exscientia
Other recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
January 2024
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Presentation
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io